Hereditary Transthyretin-mediated (hATTR) Amyloidosis research hub

Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program

This study is gathering information on pregnant women who have been exposed to patisiran-LNP. Its aim is to understand how the medicine affects pregnancy, the mother's health, and the baby's health. This helps doctors learn more about using patisiran safely during pregnancy for hereditary ATTR amyloidosis.